We are privileged to be invited by the Editor to comment on the article by Kanter et al.' in this issue of TRANSFUSION purporting a lack of value in obtaining a p value of c0.05 (95% confidence level) when performing antibody identification studies. We are especially concerned that the vast majority of technologists performing these studies will now reject the "3+/3-rule" promulgated by their mentors. This can only have a negative impact on patient care. Kanter et al. claim However, the p value, or the level of significance, is also "the probability of rejecting a true null hypothesis." In this sense, Judd is also correctn2 If the null hypothesis is indeed true, then p is the probability of obtaining the observed results by chance. While one can argue the "science" of statistics, it is imperative not to lose sight of the fact that application of the 3+/3-rule is but one of several measures used to enhance the quality-and hence, the accuracy-of antibody identification. In addition to validating negative antiglobulin tests with IgG-coated RBCs, other measures (notable exceptions aside) include confirming 1) that the test phase of reactivity is consistent with the concluded specificity; 2) that the an- tigen to which the serum is deemed to contain alloantibody is absent from the autologous RBCs; 3) that the concluded specificity is consistent with results of the initial antibody detection tests; and 4) that units lacking antigens to which the serum is deemed to contain antibody are crossmatchcompatible. Further, most workers utilize reagent RBC panels of 8 to 11 samples, and the confidence level obtained is often far greater than 95 percent. However, the 3+/3-rule do become important when multiple antibodies are present and the numbers of positive and negative samples are limited.
In calculations of the probability that a particular antibody is present, the sensitivity and specificity of the test method employed also must be taken into consideration. The probability (call it p) that a positive test with an antigenpositive RBC sample is a true positive (i.e., is due to the presence of specific antibody) is equal to the predictive value of a positive test. The probability (call it q) that a negative test is a true negative is equal to the specificity of the method used. Assuming that individual serologic tests are independent, the probability that the decision rule will be met is given by the formula r = (141 -p)") (1 -(1 -q)"), where n is the number of antigen-positive and antigen-negative RBC samples used (e.g., 2 or 3). The rate of identification failures per 1000 samples is given by lOOO(l-r). Table 1 gives the likelihood that an antibody is present given either a 3+/3-rule (criterion used by US workers) or a 2+/2-rule (UK requirement), assuming different levels of test sensitivity and specificity It is evident that using 2 antigen-positive and 2 antigen-negative RBC samples significantly reduce the confidence one can have in antibody identification even with excellent test performance.
We have seen the consequences of too many misidentified antibodies not to come to believe that it would be less than prudent to encourage workers to forget the 3+/3-rule or any of the other quality assurance measures that are part of good laboratory practice.
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